JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2026-02-06 ms8000001329628421 来自广东省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤学;肿瘤代谢
经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了

57 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2026-02-06 ms8000001329628421 来自广东省

这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们

57 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-11-20 googsci 来自美国

大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？

82 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-08-26 ms1000000131747572 来自安徽省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：细胞代谢
经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛

116 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-10-16 148aa218m20(暂无昵称) 来自山东省

Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果

83 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-08-31 ms7000002977722171 来自上海

去年投的，
8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。
后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。
另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。

101 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-05-14 ms6000000270780569 来自广西

Running technical checks要多久啊

115 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2024-08-26 1811e984f8m 来自安徽省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤分子生物学
经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。

241 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-02-25 124d4ad8m98暂无昵称来自广东省

说水刊的又没发过子刊的，能否发一篇水刊再说话

159 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299926, encodeId=fe7d229992683, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤代谢 经验分享：这个杂志和Cancer letters哪个杂志好，请教一下在座的各位大佬，准备投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:55:35 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2299925, encodeId=af8c229992573, content=这个杂志和CANCER LETTERS哪个更好呢？？？？目前在投，先投哪个呢？？？？各位大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db2e5609178, createdName=ms8000001329628421, createdTime=Fri Feb 06 10:53:18 CST 2026, time=2026-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2289733, encodeId=21cb2289e3390, content=大修修回，技术审查通过后，目前状态为“The editor has invited 2 reviewer(s)”，不知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bbad1625629, createdName=googsci, createdTime=Thu Nov 20 08:45:37 CST 2025, time=2025-11-20, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2278767, encodeId=95d422e876729, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞代谢 经验分享：8月22投的，怎么到8月26还是Technical check状态啊，不是说两天就会有决定的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5316523573, createdName=ms1000000131747572, createdTime=Tue Aug 26 08:58:43 CST 2025, time=2025-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2284959, encodeId=3baa2284959c0, content=Technical check了5天，现在是with editor, 同课题组投了一篇第二天被拒稿，是不是说明Technical check合并初审了？希望有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10dd5320784, createdName=148aa218m20(暂无昵称), createdTime=Thu Oct 16 09:30:57 CST 2025, time=2025-10-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2279474, encodeId=719922e94746c, content=去年投的， 8月22日投稿后，原本以为两天能出结果，却卡在 Technical check 到 28日。 后来才知道，若稿件格式细节没对齐期刊要求，比如图表标注不规范、参考文献格式有误，编辑会花更多时间核查，建议投稿前逐句对照指南，避免耽误进度。 另外，审稿周期不算短，从投稿到接收约 4个月，期间要及时关注系统消息，以免漏掉信息，耽误进度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 21:00:24 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2264943, encodeId=cfcd226494360, content=Running technical checks要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Wed May 14 09:19:01 CST 2025, time=2025-05-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222448, encodeId=7ed92222448b0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤分子生物学 经验分享：目前即时影响因子：7.45分，明年大概率能到12分。在影响因子下滑的时代，能连续多年维持10分以上，相当不容易，尤其是杂志并没有通过一些非常规手段：如，提前大半年发表文章，发表大量letter，发表过高比例的review，发表大量会议摘要，组件青年编委引用团队等，来操纵影响因子。被cancer research, 大CDD，advanced science 等拒了朋友，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Mon Aug 26 13:08:22 CST 2024, time=2024-08-26, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2253538, encodeId=a6e322535387b, content=说水刊的又没发过子刊的，能否发一篇水刊再说话, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ca92518561, createdName=124d4ad8m98暂无昵称, createdTime=Tue Feb 25 15:15:48 CST 2025, time=2025-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2267809, encodeId=d508226e809f9, content=确实是水刊，无奈投到这个杂志恨啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Jun 03 17:59:14 CST 2025, time=2025-06-03, status=1, ipAttribution=上海)]

2025-06-03 Mr.Never Die 来自上海

确实是水刊，无奈投到这个杂志恨啊

125 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务